Hormonal regulation of mRNA stability and RNA–protein interactions in the pituitary

J M Staton, A M Thomson and P J Leedman

Laboratory for Cancer Medicine and University Department of Medicine, Royal Perth Hospital and University of Western Australia, Western Australian Institute for Medical Research, Perth WA 6000, Australia

(Requests for offprints should be addressed to P J Leedman, University Department of Medicine, Royal Perth Hospital, Box X2213 GPO, Perth, WA 6001, Australia; Email: peterl@cyllene.uwa.edu.au)

ABSTRACT

Regulating gene expression from DNA to protein is a complex multistage process with multiple control mechanisms. Transcriptional regulation has been considered the major control point of protein production in eukaryotic cells; however, there is growing evidence of pivotal posttranscriptional regulation for many genes. This has prompted extensive investigations to elucidate the mechanisms controlling RNA processing, mRNA nuclear export and localization, mRNA stability and turnover, in addition to translational rates and posttranslational events. The regulation of mRNA stability has emerged as a critical control step in determining the cellular mRNA level, with individual mRNAs displaying a wide range of stability that has been linked to discrete sequence elements and specific RNA–protein interactions. This review will focus on current knowledge of the determinants of mRNA stability and RNA–protein interactions in the pituitary. This field is rapidly expanding with the identification of regulated cis-acting stability-modifying elements within many mRNAs, and the cloning and characterization of trans-acting proteins that specifically bind to their cognate cis elements. We will present evidence for regulation of multiple pituitary genes at the level of mRNA stability and some examples of the emerging data characterizing RNA–protein interactions.

Journal of Molecular Endocrinology (2000) 25, 17–34

INTRODUCTION

Though small, the pituitary, which is situated centrally in the sella turcica, is a major gland that synthesizes and secretes at least six hormones essential for maintaining body metabolism and homeostasis, in addition to mental function. These hormones regulate such diverse functions as growth (growth hormone, GH) and development and function of the thyroid gland (thyroid stimulating hormone, TSH), adrenal cortex (corticotropin, ACTH), male and female gonads (follicle stimulating hormone, FSH; leutinising hormone, LH) and breasts (prolactin, PRL). The posterior pituitary contains the termini of neurons originating from the hypothalamic nuclei responsible for synthesis of oxytocin and arginine vasopressin (AVP), hormones involved in suckling and body water homeostasis, respectively. Lesions in the pituitary often produce tumors and symptoms referable to under- or overexpression of these hormones.

There has been great interest in understanding the regulation of expression of each of the pituitary hormones ever since 1886, when Pierre Marie described the association of pituitary enlargement and acromegaly. How these hormones regulate the expression of other genes is also of great interest. Each pituitary hormone has been purified, characterized, cloned and its functional roles clearly delineated. Complex feedback loops have been described for many of the hormones; however, we are only just beginning to understand the complexity of the regulation of expression of the genes coding for each of these hormones. This is also true
in the study of regulation of their cognate receptors and other target genes.

Regulation of gene expression occurs at multiple levels, including transcription, RNA processing, mRNA nuclear export and localization, mRNA decay, translation and posttranslational events. However, the focus of this review will be on the current knowledge of posttranscriptional regulatory mechanisms at the level of mRNA stability. A large number of hormones have been shown to influence the mRNA stability of both non-pituitary and pituitary genes. There will be a noticeable bias towards the anterior pituitary, as this reflects the current research status, though a few examples do exist for posttranscriptional gene regulation in the posterior pituitary. Before embarking on a detailed discussion of the pituitary, in the following sections we provide an overview of the mechanisms involved in the regulation of mRNA stability.

**mRNA STRUCTURE AND FUNCTION AND RNA–PROTEIN INTERACTIONS**

After transcription, pre-mRNAs undergo major processing in the nucleus, whereby introns are removed and exons ligated (mRNA) within a RNA–protein complex known as the spliceosome. The coding sequence of eukaryotic mRNAs is flanked by their 5′ and 3′ untranslated regions (UTRs) (Fig. 1). The 5′ and 3′ UTRs of mRNAs may contain cis-acting elements that control the translation, degradation and localization of transcripts (Wilson & Brewer 1999). In addition, the 5′ and 3′ terminal nuclear modifications of eukaryotic mRNAs, the cap (7mGpppN) and poly(A) tail respectively, play critical roles in mRNA translation and stability (Wickens & Stephenson 1984, Strickland et al. 1988, Gallie 1991, Keller & Minvielle-Sebastia 1997, Wickens et al. 1997, Deo et al. 1999) (Fig. 1). RNA transport from the

---

**FIGURE 1.** Factors affecting mRNA stability: locations of mRNA sequence elements involved in regulating mRNA decay. (1) Cap structure, (2) 5′UTR sequences, (3) premature termination codons, (4) open reading frame sequences, (5) 3′UTR sequences including stem-loops and (6) AU-rich elements, and (7) the poly(A) tail. The mRNA may be protected from degradation by the binding of RNA-binding proteins (octopuses) and cap-binding protein (starfish), which protect it from exonucleases (fish), or non-specific endonucleases (crab). Specific sites may be targeted by a specific endonuclease (e.g., swordfish). Adapted from Laird-Offringa (1991).

After mRNAs have been released from the nuclear export machinery, they are bound by a cytoplasmic cap-binding complex, eIF4F, that is composed of three sub-units: eIF4E (which directly contacts the 7mG cap), the RNA helicase, eIF4A, and eIF4 G (Dreyfuss et al. 1996, Sonenberg 1996, Waskiewicz et al. 1999, Pyronnet et al. 1999) which are bound in the polyribosome complex (Mangus & Jacobson 1999). eIF4E is believed to represent a rate-limiting factor in translation, and it is therefore a potential target for translational control (Marcotrigiano et al. 1999). Work from many laboratories has shown recently that the binding of the heterotrimeric complex, eIF4F, to the cap structure is required to initiate the assembly of a translation-competent ribosome on the cap-proximal region of most cellular mRNAs (Sachs et al. 1997, Waskiewicz et al. 1999, Pyronnet et al. 1999). Other proteins that bind with high affinity to this cap-proximal region block the entry of the small ribosomal subunit and repress translation (e.g., iron-responsive elements (IREs) and iron-regulatory proteins (IRPs); Muckenthaler et al. 1998, see below).

The role of the cap in mRNA stabilization has been demonstrated clearly in Saccharomyces cerevisiae, in which decapping of the 5′-terminus represents part of a common degradation pathway for stable and unstable mRNAs (Caponigro & Parker 1995, Tuite 1996, Deo et al. 1999, see below). Decapping is preceded by deadenylation (removal of the poly(A) tail at the 3′-terminus), which reflects the role of the poly(A) tail in translation regulation and mRNA turnover and indicates an important communication between the two termini (Strickland et al. 1988, Jacobson & Peltz 1996, Tanguay & Gallie 1996, Deo et al. 1999).

Inherently unstable mRNAs can approach a new steady-state level more rapidly than stable mRNAs after changes in transcriptional activity (Hargrove & Schmidt 1989, Beelman & Parker 1995, Wilson & Brewer 1999). This property of unstable mRNAs allows their cytoplasmic concentrations, and hence their potential for translation, to be altered quickly in response to a change in the transcription rate. A number of mRNAs display altered stability in response to hormonal, developmental and environmental factors (Wilson & Brewer 1999, Williams et al. 1993). These inducible effects on mRNA stability have the potential to change cytoplasmic mRNA concentrations rapidly without alteration in transcriptional activity, or to augment the magnitude of mRNA induction by coordinating changes in transcription and mRNA stability.

In summary, specific fundamental RNA–protein interactions occur within both the nucleus (mRNA processing and localization) and the cytoplasm (localization, translation, mRNA stability) of eukaryotic cells, and it is these interactions that govern the subsequent rate of decay of a particular mRNA. This review will focus predominantly on cytoplasmic mRNA decay in the pituitary.

**CYTOPLASMIC mRNA DECAY: SEQUENCE DETERMINANTS**

mRNA decay is not a random, indiscriminate nuclelease degradation process, but a precise process dependent on a variety of specific cis-acting stability-modifying mRNA sequences and trans-acting protein factors (Figs 1, 2). Nucleases, mRNA sequence elements and regulated RNA-binding proteins required for the promotion or inhibition of mRNA decay have been identified, and the molecular mechanisms involved are being elucidated. Generically, mRNA decay is triggered by at least three types of initiating event: poly(A) tail shortening, arrest of translation at a premature nonsense codon, and endonucleolytic cleavage (Figs 1, 2) (Stevens 1993). Steps subsequent to poly(A) tail shortening or premature translational termination converge in a pathway that progresses from removal of the 5′ cap to exonucleolytic digestion of the body of the mRNA (Jacobson & Peltz 1996, Wilson & Brewer 1999). Fragments generated by endonucleolytic cleavage are most probably removed by exonucleolytic decay also (Fig. 2). Recent studies have indicated that decay of mRNA commences while the mRNA is still being translated and is still attached to the polyribosomal complex (Mangus & Jacobson 1999). However, translation initiation is required to induce mRNA decay (Posch et al. 1999). The role of different mRNA sequences and structures (cis elements) and RNA-binding proteins (trans elements) in the determination of mRNA decay will be discussed below.

**Exonuclease mRNA decay: poly(A) tail-dependent degradation**

*Role of 5′ cap and poly(A) tail*

The mRNA 5′ cap structure generally remains unchanged after mRNA export into the cytoplasm. The 5′–5′ phosphodiester bond of the cap makes it inherently resistant to general ribonucleases.
DEADENYLATION-DEPENDENT DECAY

POLY(A) TAIL SHORTENING

DEADENYLATION-INDEPENDENT DECAY

DEADENYLATION-INDEPENDENT DECAPPING

ENDONUCLEOLYTIC CLEAVAGE

5’ TO 3’ DECAY

3’ TO 5’ DECAY

5’ TO 3’ DECAY

FIGURE 2. mRNA decay pathways in eukaryotes. The top pathway depicts deadenylation-dependent decay, followed by decapping and 5’–3’ decay, or 3’–5’ decay by exonucleases and/or endonucleases. The vast majority of eukaryotic mRNAs may undergo decay in this way unless they are specifically targeted for rapid deadenylation-independent decapping (bottom) by a nonsense codon, or for endonucleolytic cleavage, by the presence of a cleavage site. After deadenylation-independent decapping (bottom pathway), mRNA is degraded in a 5’–3’ manner. Endonucleolytic cleavage of mRNA may serve as a one-step deadenylation that leads to decapping and 5’–3’ decay. Adapted from Beelman & Parker (1995) with permission.
(Furuichi et al. 1977, Shimotohno et al. 1977), though binding of the eIF4 G complex may also be responsible for protecting this region from nuclease attack (Stevens 1993, Dreyfuss et al. 1996).

Most eukaryotic mRNAs have a 3’ poly(A) tract; though contentious, this is not regarded as a determinant of mRNA stability, even though it does influence mRNA decay (Strickland et al. 1988). Poly(A) tracts are gradually shortened in the cytoplasm in an mRNA- and organism-specific manner, and may be completely removed in some cases (Wilson & Brewer 1999, Imataka et al. 1998, Jacobson & Peltz 1996). In some instances, shortening of the tail to an oligo(A) form is the rate-determining event that triggers turnover of the body of the transcript (Jacobsen & Peltz 1996). This mechanism exists in eukaryotes mainly to ensure that aberrant mRNAs are not translated, but is also related to the degradation process initiated in non-aberrant mRNAs that all contain stop codons.

Role of sequence elements
The differences in decay rates in stable and unstable mRNAs are attributable to the presence or absence of specific sequence elements. With the exception of the stabilizer sequences that appear to be associated with the yeast PGK1 mRNA (Heaton et al. 1992, Peltz et al. 1993) and the human γ-globin mRNA (Weiss & Liebhaber 1995), all identified elements promote mRNA destabilization. These sequences include the well characterized adenosine (A)+ uridine (U)-rich elements (AREs) located in the 3’UTRs of mammalian mRNAs, in addition to other sequences in mRNA coding regions, 3’UTRs and 5’UTRs.

AU-rich elements (AREs) In 1986, Shaw & Kamen observed that an ARE in the 3’UTR of granulocyte-macrophage colony-stimulating factor (GM-CSF) mRNA could stimulate the degradation of the normally stable β-globin mRNA. Similarly, the 3’UTR of c-fos, which contains a 69 nt ARE, reduced the stability of β-globin mRNA (Chen & Shyu 1995, Chen et al. 1995). Subsequently, AREs that function as RNA destabilizing elements have been found in numerous mRNAs, including c-myc, junB, nur77, β-interferon, interleukin (IL)-1α and IL-3 mRNAs (Cleveland & Yen 1989, Chen & Shyu 1994, 1995, Gorospe & Baglioli 1994). The sequence consensus for the ARE is loosely defined as a pentamer comprising AUUUA, repeated once or several times within the 3’UTR. It is often found within a U-rich region of the mRNA. However, recent work has suggested that a nonamer, UUAUUUA(U/A)(U/A), is more indicative of rapid destabilization (Lagnado et al. 1994, Zubiaga et al. 1995). It is now becoming clear that it is the combination of functionally and structurally distinct sequence motifs, such as AU-pentamers, nonamers and U-rich stretches, that determines the ultimate destabilizing ability of each particular ARE.

Other 3’UTR elements associated with poly(A) tail shortening There is a growing number of non-ARE 3’UTR instability elements associated with poly(A) tail shortening. Two well-characterized cis elements have been identified within the 3’UTRs of the ribonucleotide reductase R1 and R2 mRNAs (Chen et al. 1993, Amara et al. 1995).
1995, Fan et al. 1996); regulation of expression of R2 is especially important in tumorigenesis. R1 and R2 mRNAs contain sequences within their 3′UTRs that are bound by the specific proteins R1 BP and R2 BP, respectively (Chen et al. 1993, Amara et al. 1995). Increased binding of these RNA-binding proteins leads to accelerated R1/R2 mRNA decay (Amara et al. 1995, Fan et al. 1996). Interestingly, tumorigenesis was associated with decreased binding of R1 BP and R2 BP to their respective cognate 3′UTR mRNA sequences, which resulted in overexpression of R1 and R2 proteins.

**Coding region elements** Destabilizing sequences are not limited to the 3′UTR and can be found throughout the mRNA. The open reading frame (ORF) of β-tubulin contains an N-terminal tetrapeptide that provides a signal for rapid decay of the mRNA when tubulin monomer is in excess (Yen et al. 1988). Similarly, the c-fos mRNA contains a second destabilizing sequence within the ORF; however, it is only utilized when the message is transiently expressed after growth factor stimulation (Shyu et al. 1989). In addition, c-myc has a cis element located within the coding region (Shyu et al. 1989).

**Endonuclease mRNA decay: poly(A) tail-independent degradation**

Deadenylation-independent endonuclease degradation of certain mRNAs does occur and cleavage sites have been identified in the 3′UTRs and coding regions of a small number of mRNAs. Examples of transcripts that undergo degradation by this method include mammalian 9E3 (Stoekle & Hanafusa 1989), insulin-like growth factor-II (Nielson & Christiansen 1988), transferrin receptor (TfR) (Binder et al. 1989, 1994) and Xenopus Xihbox2B (Brown et al. 1993) mRNAs. Sequence-specific endonuclease target sites are likely to be limited to individual mRNAs or classes of mRNAs, and their presence probably allows for specific control of the decay rates of these particular transcripts.

Endonucleolytic cleavage of some of these mRNAs is regulated by RNA-binding proteins that bind in the vicinity of the cleavage site that renders the site inaccessible to nucleolytic attack. One of the most studied examples is the iron-responsive element (IRE) within the TfR mRNA, in which decay is regulated, not only in response to cellular iron concentrations, but to multiple stimuli (Klausner et al. 1993, Leedman et al. 1996, Posch et al. 1999, Thomson et al. 1999a). The 3′UTR of this mRNA contains five distinct stem-loop structures capable of binding the IRE-binding protein (iron-regulatory protein, IRP) (see below). Conditions that favor binding of the IRP lead to stabilization of the mRNA sequence as it protects the functional cleavage site between two of the IREs (Lok & Ponka 1999, Posch et al. 1999). Destabilization of the TfR mRNA occurs in conditions that favor a reduction of IRP affinity for the TfR IREs (Fig. 3).

Endonucleolytic cleavage of some mRNAs is dependent upon current translation, and this may reflect ribosome displacement of bound RNA-binding proteins in the coding region, the melting of secondary structures that leads to exposure of linear sequences, or accumulation of specific endonucleases (Jacobsen & Peltz 1996, Deo et al. 1999). Deadenylation or endonucleolytic cleavage may be two independent means of disrupting RNA–protein complexes and creating substrates for exonucleases responsible for the bulk of mRNA degradation.

**CYTOPLASMIC mRNA: TRANS-ACTING RNA-BINDING PROTEINS**

Realization of the complexity of cis elements led to the development of assays to detect RNA-binding proteins targeting these regions. Development of the RNA electrophoretic mobility shift assay (REMSA) and u.v. cross-linking assay (Liebold & Munro 1988, Wilson & Brewer 1999, Thomson et al. 1999b), which involve the incubation of a radiolabeled RNA probe with cell protein extract, transformed investigation in this area. With these assays, specific RNA–protein interactions were readily detected, the effects of various treatments easily discerned, and the size of the proteins determined. Identification of specific proteins was made with the addition of specific antibodies that supershift the protein band in a REMSA. Using these approaches, regulated RNA-binding proteins have been characterized in the pituitary that target several different mRNAs, including TSHβ and thyrotropin-releasing hormone receptor (TRHR) mRNAs. In the past several years, a vast array of proteins has been described that bind to various mRNA sequences implicated in mRNA destabilization. However, to date, few of these proteins have been shown to play a definite role in modulating mRNA turnover. Identification and cloning of some of these protein factors has provided enormous insight into the mechanisms involved in regulated mRNA turnover.
**Poly(A) binding protein (PABP)**

PABP is a highly conserved 71 kDa protein found in the cytoplasm and nucleus that binds to the poly(A) tail with high affinity and plays an important part in regulating its length (Blobel 1973, Baer & Kornberg 1983, Bernstein et al. 1989, Jackson & Standart 1990, Munroe & Jacobson 1990, Gørlach et al. 1994, Smith et al. 1997, Afonina et al. 1998, Deo et al. 1999). PABP contains four RNA-recognition motifs (RRMs 1–4) and a proline-rich carboxy terminus (Burd et al. 1991, Deo et al. 1999). The cocrystal structure of human PABP with poly(A) was recently determined (Deo et al. 1999). RRM1 and RRM2 are responsible for poly(A) binding (Deo et al. 1999), but RRM4 is mainly involved in non-specific polypyrimidine RNA binding (Smith et al. 1997). Recent studies have shown that PABP is also able to bind to AU-rich stretches of mRNA (Afonina et al. 1997). Interestingly, RNA binding, but not high-affinity poly(A) binding, is correlated with the ability of PABP to sustain yeast viability (Sachs et al. 1987), reinforcing the notion that PABP plays a major role in regulating mRNA stability, independently of its role in poly(A) length regulation (Caponigro & Parker 1995, Deardo & Sachs 1997, Craig et al. 1998, Deo et al. 1999).

mRNA stabilization by PABP requires current translation of the mRNA, and PABP preferentially stabilizes mRNAs that decay independently of deadenylation-dependent, with little or no effect on mRNAs that decay independently of deadenylation.
(Coller et al. 1998). A model has been postulated in which PABP acts to hold both ends of an mRNA in close proximity. PABP does interact in vitro with the translation initiation factors eIF4 G, eIF4F and eIF4B in plants and yeast, both in the presence and the absence of poly(A) RNA (Le et al. 1997, Tarun & Sachs 1996, Gallie 1998). In humans, eIF4 G has recently been shown to bind to PABP (Imataka et al. 1999). This interaction inhibits poly(A)-dependent translation, but has no effect on translation of deadenylated mRNA (Imataka et al. 1999). Mammalian PABP also binds to PABP-interacting protein-1 (PAIP-1) (Craig et al. 1998). PAIP-1 shares 25% homology with a 470 amino acid region of mammalian eIF4 G. Remarkably, increasing the concentration of PAIP-1 in vitro resulted in a modest 2-8-fold increase in translation in COS-7 cells (Craig et al. 1998), suggesting an important role for this protein in the regulation of translational efficiency (Deo et al. 1999).

**AU-rich element binding proteins (AUBPs)**

A family of proteins has been characterized by REMSA that bind to AU-rich, and sometimes U-rich RNAs with high affinity. In most cases, binding of these AUBPs (30–45 kDa) increases the turnover of ARE-containing mRNAs (DeMaria & Brewer 1996, Joseph et al. 1998).

*The elav-like proteins*

One of the best characterized AUBPs is HuR, a 36 kDa member of the embryonic lethal abnormal vision (elav) family of RRM-containing RNA-binding proteins (Levine 1993, Joseph et al. 1998). The elav-like protein family contains four proteins, namely HuC, Hel-N1, HuD and HuR (Myer et al. 1997). HuR has been shown to bind with high affinity to ARE sequences (Levine 1993, Joseph et al. 1998). Most importantly, HuR has an active role in the stabilization of specific mRNAs containing AREs, such as glucose transporter 1, c-fos, GM-CSF, plasminogen activator inhibitor type 2 and p21waf1 (Jain et al. 1997, Levy et al. 1998, Fan & Steitz 1998, Maurer et al. 1999, Joseph et al. 1998). The ability of elav/Hu proteins to stabilize ARE-containing mRNAs was confirmed recently using an in vitro system (Ford et al. 1999). Interestingly, HuR appears to shuttle between the nucleus and the cytoplasm, and it has been postulated that this function is to chaperone AREs out to the cytoplasm (Fan & Steitz 1998). Aberrant shuttling may therefore render the ARE susceptible to decay in the cytoplasm. HuR may also have an effect at the translational level, coupling mRNA stability and translation, an association studied extensively by Jacobson & Peltz (1996).

**AU-binding factor 1 (AUF1)**

The proto-oncogene, c-myc, contains ARE sequences in the 3′UTR of its mRNA. These sequences act as destabilizing elements and bind the RNA-binding protein, AUF1 (Brewer 1991, Zhang et al. 1993, DeMaria et al. 1997, Wilson & Brewer 1999, Wilson et al. 1999). AUF1 has been implicated in the regulation of many cytokine and G protein-coupled receptor mRNAs (Wilson & Brewer 1999), and plays a major role in development (Lafon et al. 1998). Different splice variants of AUF1 exist and all bind to ARE sequences. The 37 and 40 kDa isoforms are found throughout the cell, whereas the p42 and p45 isoforms reside only in the nucleus (Wilson & Brewer 1999). Interestingly, four 3′UTR splice variants also exist that alter expression of AUF1 (Wilson et al. 1999). AUF1 contains two non-identical RRM s that interact with other sequences within the protein structure to facilitate RNA-binding (Wilson & Brewer 1999). AUF1 is also known to bind to eIF4 G and PABP. AU-rich mRNA decay is associated with displacement of eIF4 G from AUF1, ubiquitination of AUF1 and degradation of AUF1 by proteasomes (Laroia et al. 1999).

**Other ARE binding proteins**

An intriguing finding has been the isolation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and enoyl coenzyme A (CoA) hydratase from ARE-binding protein screens (Nagy & Rigby 1995, Wilson & Brewer 1999). These proteins contain ARE-binding motifs, but their significance in RNA turnover has yet to be established.

**Non-ARE-binding proteins**

Reports characterizing novel non-ARE RNA-binding proteins are increasing, although we shall focus on the most studied of these proteins, the IRPs. Two mammalian isoforms exist, IRP1 and IRP2, IRP1 acting as a cytoplasmic aconitase under conditions favoring low-affinity mRNA binding (Klausner et al. 1993, Leedman et al. 1996, Thomson et al. 1999a).

Posttranslational modification of IRP1 and IRP2 alters their binding affinity for their specific cognate mRNA hairpin structures, the IREs, and controls the expression of genes posttranscriptionally. IREs present in the 5′UTR of ferritin, erythroid 5-aminolevulinate synthase and mammalian mitochondrial aconitase mediate the translational efficiency of these mRNAs (Klausner et al. 1993,
TABLE 1. Summary of non-pituitary-derived genes that are known to be regulated by hormones

<table>
<thead>
<tr>
<th>mRNA affected</th>
<th>Regulation</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitellogenin</td>
<td>mRNA stabilized 30-fold by estrogen</td>
<td>Brock &amp; Shapiro (1982)</td>
</tr>
<tr>
<td>ApoVLDII</td>
<td>mRNA stabilized and poly(A) tail increased by estrogen</td>
<td>Cochrane &amp; Deely (1988)</td>
</tr>
<tr>
<td>Ovalbumin</td>
<td>mRNA stabilized by estrogen or progesterone</td>
<td>Cox (1977)</td>
</tr>
<tr>
<td>Conalbumin</td>
<td>mRNA stabilized by estrogen or progesterone</td>
<td>McKnight &amp; Palmiter (1979)</td>
</tr>
<tr>
<td>MCH</td>
<td>mRNA stabilized by lithium</td>
<td>Presse et al. (1997)</td>
</tr>
<tr>
<td>HMG-CoA reductase</td>
<td>mRNA stabilized twofold by T₃</td>
<td>Simont &amp; Ness (1989)</td>
</tr>
<tr>
<td>NADH dehydrogenase subunit 3</td>
<td>mRNA stabilized threefold by T₃; mRNA destabilized five- to sixfold by Dex or hydrocortisone</td>
<td>Raikhinstein &amp; Hanakoglu (1993)</td>
</tr>
<tr>
<td>Vasopressin</td>
<td>mRNA stabilized by dehydration through increased poly(A) tail length</td>
<td>Zingg et al. (1988)</td>
</tr>
<tr>
<td>PAM</td>
<td>mRNA stabilized by estrogen</td>
<td>El Meskini et al. (1997)</td>
</tr>
<tr>
<td>CRH</td>
<td>mRNA stabilized 16-fold and poly(A) tail length increased by protein kinase C</td>
<td>Adler et al. (1992)</td>
</tr>
<tr>
<td>Inhibin α</td>
<td>mRNA stabilized by cAMP</td>
<td>Najmabadi et al. (1993)</td>
</tr>
<tr>
<td>Renin</td>
<td>mRNA stabilized three- to fourfold by cAMP</td>
<td>Chen et al. (1993)</td>
</tr>
<tr>
<td>Malic enzyme</td>
<td>mRNA stabilized twofold by T₃</td>
<td>Song et al. (1988)</td>
</tr>
<tr>
<td>FSHR</td>
<td>mRNA stabilized 1.5–2-fold by activin</td>
<td>Tano et al. (1997)</td>
</tr>
<tr>
<td>Casein</td>
<td>mRNA stabilized 20-fold by prolactin</td>
<td>Guyette et al. (1979)</td>
</tr>
<tr>
<td>PR</td>
<td>mRNA stabilized by LH or FSH</td>
<td>Iwashita et al. (1991)</td>
</tr>
<tr>
<td>TRHR</td>
<td>mRNA stabilized by TRH</td>
<td>Fujimoto et al. (1992b)</td>
</tr>
<tr>
<td>LH/hCGR</td>
<td>mRNA destabilized threefold by LH</td>
<td>Lu et al. (1993)</td>
</tr>
<tr>
<td>FSHR</td>
<td>mRNA stabilized sixfold by FSH</td>
<td>Tilly et al. (1992)</td>
</tr>
<tr>
<td>AR</td>
<td>mRNA stabilized by DHT</td>
<td>Yeap et al. (1999)</td>
</tr>
<tr>
<td>EGFR</td>
<td>mRNA stabilized by EGF</td>
<td>McCulloch et al. (1998)</td>
</tr>
</tbody>
</table>

Hormonal regulation of non-pituitary gene mRNA stability

Steroid hormones were one of the earliest agents shown to control the degradation of specific mRNAs and to regulate the stability of a substantial number of mRNAs. The best characterized is the stabilization of vitellogenin mRNA by estrogen (Nielsen & Shapiro 1990a). Vitellogenin mRNA levels increase >10 000-fold upon estrogen stimulation in Xenopus liver (Brock & Shapiro 1982, 1983). The estrogen-mediated increase in vitellogenin mRNA is effected by an increase in both transcription and mRNA stability (Brock & Shapiro 1982, 1983). The mRNA half-life of hepatic vitellogenin increases from 16 h to 500 h after the administration of estrogen (Brock & Shapiro 1983). Further analysis revealed that an estrogen-regulated cis-acting element was situated in the 3’UTR of vitellogenin mRNA (Nielsen & Shapiro 1990b), and required association of the mRNA with ribosomes for stabilization (Blume & Shapiro 1989). More recently, a polysome-associated protein of molecular mass 150–155 kDa was shown to bind...
specifically within a 27 nt region of a 94 nt segment (required for maximal binding) of the 3′UTR of vitellogenin mRNA in an estrogen-inducible manner (Dodson & Shapiro 1994, 1997, Dodson et al. 1995, Kanamori et al. 1998). This protein has subsequently been identified as vigilin. It is ubiquitously expressed and contains 14 human ribonucleo protein K (hnRNPK) homology (KH) domains and had previously been shown to bind tRNA (Kruse et al. 1996). The 14 KH domains in vigilin allow its interaction with multiple mRNAs that contain specific, mainly single stranded, regions that constitute long RNA binding sites (~75 nt, (A)n, CU and UC(A)n motifs) (Kanamori et al. 1998); its association with other proteins may also define binding specificity or cytoplasmic targeting. Vigilin is present in both the cytoplasm and the nucleus of cells (Kugler et al. 1996), and may be involved in shuttling of mRNAs from nucleus to cytoplasm. A clear functional role of RNA binding of vigilin has not been established (Kanamori et al. 1998), but its estrogen-regulated binding to vitellogenin mRNA and associated increase in vitellogenin mRNA stability emphasize its importance in regulating mRNA metabolism.

Other hormones known to influence posttranscriptional events include T3, which increases the stability of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase mRNA approximately threefold (Simonet & Ness 1989). This stabilization was blocked by hydrocortisone and dexamethasone, threefold (Simonet & Ness 1989). This stabilization (HMG-CoA) reductase mRNA approximately twofold (Lopez-Barachona et al. 1990). More recently, T3 was shown to increase the stability of proteolipid mRNA approximately twofold. Interest-stability of proteolipid (the major component of myelin) mRNA approximately twofold. Interestingly, T3 was shown to increase the stability of proteolipid mRNA in C6 glioma cells (Kugler et al. 1996). The 14 KH domains in vigilin allow its interaction with multiple mRNAs that contain specific, mainly single stranded, regions that constitute long RNA binding sites (~75 nt, (A)n, CU and UC(A)n motifs) (Kanamori et al. 1998); its association with other proteins may also define binding specificity or cytoplasmic targeting. Vigilin is present in both the cytoplasm and the nucleus of cells (Kugler et al. 1996), and may be involved in shuttling of mRNAs from nucleus to cytoplasm. A clear functional role of RNA binding of vigilin has not been established (Kanamori et al. 1998), but its estrogen-regulated binding to vitellogenin mRNA and associated increase in vitellogenin mRNA stability emphasize its importance in regulating mRNA metabolism.

Other hormones known to influence posttranscriptional events include T3, which increases the stability of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase mRNA approximately threefold (Simonet & Ness 1989). This stabilization was blocked by hydrocortisone and dexamethasone, each of which reduced the stability of HMG-CoA reductase mRNA five- to sixfold (Simonet & Ness 1989). More recently, T3 was shown to increase the stability of proteolipid (the major component of myelin) mRNA approximately twofold. Interestingly, retinoic acid induced a ~10-fold increase in proteolipid mRNA stability in C6 glioma cells (Lopez-Barachona et al. 1993). Other effects of T3 include the stabilization of malic enzyme mRNA in rat liver (Back et al. 1986, Song et al. 1988).

The ovary and adrenals are also sites at which hormonal regulation of mRNA stability has been observed. Treatment of ovarian granulosa cells with LH or FSH for 3 h increased progesterone receptor mRNA eight- to ninefold (Iwai et al. 1991). Incubation of adrenal cortex cells with ACTH stabilized mitochondrial mRNA (Raikhinstein & Hanukoglu 1993) and also NADH dehydrogenase subunit 3 mRNA, increasing the latter mRNA approximately 20-fold after 6 h of exposure.

An increasing number of hormones have been shown to regulate expression of their own receptor at the posttranscriptional level. For example, the stability of the epidermal growth factor receptor (EGFR) mRNA was increased more than threefold by EGF and by transforming growth factor α (TGFα) in epidermoid cancer cells (McCulloch et al. 1998), and approximately twofold by EGF and TGFβ in prostate cancer cells (Seth et al. 1999).

**Hormonal regulation of pituitary gene mRNA stability**

A large number of genes expressed in the pituitary are regulated at the level of mRNA stability (Table 2). For example, mRNA stability of the common α-glycoprotein subunit was recently compared with that of LHβ and FSHβ mRNAs (Bouamoud et al. 1992). Interestingly, there was broad variation in the basal half-life for each mRNA, with values of 1-0, 6-5 and 44 h for FSHβ, the α-subunit and LHβ mRNAs, respectively. Rapid disappearance of these mRNAs was associated with a progressive shortening of the poly(A) tail (Bouamoud et al. 1992). In addition, the stability of each of these mRNAs was regulated extrinsically by various ligands. For example, the mRNA stability of the α-subunit was increased six- to sevenfold in the presence of gonadotropin releasing hormone (GnRH) in αT3 pituitary cells (Chedrese et al. 1994). Similarly, GnRH stabilized LHβ mRNA, and this stabilization was further augmented by progesterone, or a combination of estrogen and progesterone (Park et al. 1995). Interestingly, FSHβ subunit mRNA, but not α-subunit or LHβ mRNA, was stabilized by testosterone in male rat gonadotropes (Paul et al. 1990). In a separate study, estrogen was shown to increase the mRNA stability of another pituitary hormone receptor, TRHR, approximately twofold in rat pituitary primary cultures (Kimura et al. 1994).

We and others have shown that TSHβ subunit mRNA is regulated posttranscriptionally by T3, reducing its half-life from 24 h to approximately 8 h in both rat and murine pituitary cells (Krane et al. 1991, Staton & Leadman 1998). This reduction in mRNA stability was accompanied in both species with a reduction in the length of the poly(A) tail from 160-180 to ~30 nt. TSHβ mRNA was also destabilized by bromocryptine, which reduced the half-life approximately twofold (Levy & Lightman 1990).

The effect of T3 on the posttranscriptional regulation of GH expression has been studied extensively by several groups. T3 destabilized and
deadenylated GH mRNA in rat pituitary cells (Murphy et al. 1992). However, when T₃ was combined with dexamethasone, a 50-fold increase in GH mRNA was observed, predominantly as a result of stabilization of the mRNA associated with an increase in the length of the poly(A) tail (Diamond & Goodman 1985, Paek & Axel 1987, Jones et al. 1990).

There are abundant examples of pituitary ligands regulating the mRNA stability of their own receptor in non-pituitary tissue. LH decreased the stability of LH/hCG-receptor mRNA approximately three-fold in rat ovary primary cultures (Lu et al. 1993). The stability of FSH- and activin-stabilized FSH receptor (FSHR) mRNA is increased several-fold in ovarian granulosa cells (Tilly et al. 1992, Tano et al. 1997). Recent studies identified an LH receptor mRNA stability LH-receptor RNA-binding protein (LRBP-1) of molecular mass 50 kDa that bound to a 180 nt region within the ORF of LH receptor mRNA (Kash & Menon 1998). Moreover, the binding of LRBP-1 increased approximately three-fold after 12 h of incubation with LH (Kash & Menon 1998).

Very little is known about posttranscriptional regulation of gene expression in the posterior pituitary. In 1988, Zingg et al. observed that dehydration caused an increase in the poly(A) tail length of vasopressin (from 210 nt to 330 nt), associated with increased mRNA stability. Robinson et al. (1988) investigated this further and determined that the variation in length occurred in the suprachiasmatic hypothalamic nuclei, the location of an endogenous mammalian circadian pacemaker. These results suggested that the variation in mRNA poly(A) tail length may underlie the circadian rhythm of vasopressin peptide levels in cerebrospinal fluid (Robinson et al. 1988).

In summary, the regulation of expression of hormones secreted by the pituitary has been studied extensively, the vast proportion being regulated, in part, at the level of mRNA stability. However, the mechanisms underlying these changes in mRNA turnover for the majority of these genes remain largely unknown.

### Hormonal regulation of RNA-protein interactions and mRNA decay in the pituitary

There are a few examples of regulated mRNA decay in the pituitary for which RNA–protein interactions have been more clearly defined.

### Posttranscriptional regulation of TSHβ mRNA expression

Several studies have shown that T₃ decreases TSHα- and TSHβ-subunit steady-state mRNA levels, in part as a result of reduced transcription (Surks & Litschitz 1977, Ross et al. 1983, Shupnik et al. 1985). TSHβ mRNA is also regulated by T₃ at the posttranscriptional level, accompanied by a shortening of the poly(A) tail (Krane et al. 1991, Staton & Leedman 1998). In the presence of actinomycin D, but the absence of T₃, TSHβ mRNA was deadenylated without inducing rapid mRNA decay, suggesting that deadenylation alone was not sufficient for the acceleration of TSHβ mRNA turnover.

We recently isolated a cis-acting element located within the 70 nt of the 3’UTR of TSHβ mRNA (unpublished observations). This sequence does not

---

**Table 2. Summary of pituitary-derived genes that are known to be regulated by hormones**

<table>
<thead>
<tr>
<th>mRNA affected</th>
<th>Regulation</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRHR</td>
<td>mRNA stabilized twofold by estrogen</td>
<td>Kimura et al. (1994)</td>
</tr>
<tr>
<td>TSHβ</td>
<td>mRNA destabilized three- to fourfold and poly(A) tail shortened by T₃; mRNA destabilized twofold by bromocriptine</td>
<td>Staton &amp; Leedman (1998)</td>
</tr>
<tr>
<td>FSHβ</td>
<td>mRNA stabilized twofold by testosterone</td>
<td>Levy &amp; Lightman (1990)</td>
</tr>
<tr>
<td>GH</td>
<td>mRNA stabilized and poly(A) tail length increased by glucocorticoids; mRNA stabilized twofold by T₃</td>
<td>Paul et al. (1990)</td>
</tr>
<tr>
<td>LHβ</td>
<td>mRNA stabilized 50-fold and poly(A) tail length increased by Dex+T₃; mRNA stabilized by GnRH; GnRH-induced mRNA stability augmented with progesterone or progesterone+estrogen</td>
<td>Paek &amp; Axel (1987)</td>
</tr>
<tr>
<td>LH/FSH/TSH α-subunit</td>
<td>mRNA stabilized six- to sevenfold by GnRH</td>
<td>Park et al. (1995)</td>
</tr>
</tbody>
</table>

Dex, Dexamethasone.
contain any AREs or other well characterized cis-acting destabilizing elements (Leedman et al. 1995). Interestingly, it was the target for T3-regulated cytoplasmic RNA-binding proteins derived from murine thyrotrope cells. U.v. cross-linking assays identified two major TSHβ mRNA specific RNA-binding complexes (TSHβ BP1 and BP2) of molecular mass ~60 and ~72 kDa (unpublished observations). Remarkably, we demonstrated that the 72 kDa complex contained PABP. A proposed model in which T3 coordinately regulates the shortening of the poly(A) tail and the activity of RNA-binding proteins binding specifically to the cis-acting element within the 3'UTR of TSHβ mRNA is illustrated in Fig. 4. The role of PABP in this process is still being elucidated. However, our findings suggest a novel dual role for PABP in the deadenylation and accelerated decay of TSHβ mRNA, by its ability to bind poly(A) and non-poly(A) sequences, respectively. Cloning and characterization of the other TSHβ mRNA RNA-binding protein(s) will facilitate careful functional analysis of the role of each protein in regulated TSHβ mRNA decay, and provide considerable insight into the mechanisms of action of T3 at the posttranscriptional level.

**Figure 4.** Schematic model of T3-mediated decay of TSHβ mRNA in pituitary cells. In the absence of T3, TSHβ mRNA is polyadenylated and stable; in the presence of T3, it is deadenylated and undergoes decay by exonucleases and/or endonucleases. T3 regulates binding of 3'UTR mRNA-binding proteins, PABP and TSHβ BP2, which play a role in facilitating TSHβ mRNA decay.

**Posttranscriptional regulation of TRHR mRNA**

Posttranscriptional regulatory mechanisms have been shown to have a critical role in the regulation of TRHR gene expression (Fujimoto et al. 1992a, b). Several actinomycin D chase experiments have shown that TRH regulates TRHR gene expression at the level of mRNA turnover. Endogenous TRHR mRNA in rat pituitary cells was decreased by TRH, and increased by estradiol (E2) (Kimura et al. 1994). In rat pituitary cells stably transfected with murine TRHR, TRH destabilized TRHR mRNA (Fujimoto et al. 1992a). A cell free mRNA decay assay showed that TRH regulated RNase activity in rat pituitary GH3 cells, governed by specific sequences within the 3'UTR of TRHR mRNA (Narayan et al. 1992). In deletion studies, a truncated form of the TRHR missing the entire 3'UTR (~2 kb) was more stable than the full-length receptor. Interestingly, deletion of the last 143 nt from the 3'UTR, which formed a stable stem-loop structure, prevented TRH from enhancing TRHR mRNA decay (Narayan et al. 1992). Thus the TRHR 3'UTR appears to contain two distinct regions. One, the stem-loop at the 3' end of the 3'UTR, is necessary for conferring TRH-regulated TRHR mRNA degradation. The other,
which is less well defined, comprises a cis-acting element responsible for TRH-mediated decay. Within this region, there are several AU-rich putative mRNA stability modifying cis-acting regions that are conserved across species. There are four AUUUA pentamers, including one interesting double pentamer, AUUUAUUUA, motif just 5′ to the stem-loop in mouse and rat. We presume that one or more of these AU-rich regions comprise the cis element. Interestingly, the human TRHR 3′UTR (∼0·9 kb) contains many AU-rich regions and a structurally conserved stem-loop at the 5′ end of the 3′UTR.

We recently identified RNA-binding proteins unique for each of the aforementioned TRHR AU-rich regions and the stem-loop in cytoplasmic extracts from thyrotrope and lactotrope pituitary cells (unpublished observations). Binding activity of these RNA–protein complexes was rapidly upregulated approximately fivefold in both cell types after TRH and phorbol-12 13-myristate acetate stimulation. In marked contrast, however, T3 downregulated binding activity of these RNA–protein complexes. These data provide the first evidence for divergent regulation by TRH and T3 of the binding of these novel RNA-binding proteins to the stem-loop and AU-rich regions of TRHR mRNA. This divergent hormone-regulated change in binding is consistent with the opposing physiologic actions of T3 and TRH expression in these cell types. Furthermore, these data suggest that a complex system of hormonally regulated RNA–protein interactions is involved in the control of TRHR mRNA decay in the pituitary.

Posttranscriptional regulation of ferritin gene expression in the pituitary

As alluded to above, control of mammalian intracellular iron homeostasis is largely due to posttranscriptional regulation of binding by IRPs to IREs within ferritin and TfR mRNAs. IRP binding is tightly controlled such that it responds to changes in intracellular iron requirements in a coordinate manner, differentially regulating ferritin mRNA translational efficiency and TfR mRNA stability. Most interestingly, we have found recently that T3 and TRH are capable of modulating the binding of two pituitary IRPs, IRP1 and IRP2, to a ferritin IRE (Thomson et al. 1999a). TRH was found to regulate ferritin protein concentrations similarly in thyrotrope and lactotrope cells but, unexpectedly, differentially modulated the binding of IRP1 and IRP2 to a ferritin IRE. However, T3 downregulated IRP binding in both cell types (unpublished observations). TRH induced an increase in IRP binding in thyrotropes, associated with IRP phosphorylation and protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) activation. However, in lactotropes, TRH decreased IRP binding despite PKC and MAPK activation. These data demonstrate a divergent and cell-specific regulation of IRP binding by TRH and T3 in the pituitary. They also represent a further example of a specific RNA–protein interaction in the pituitary that was divergently regulated by TRH and T3.

These data suggest that multiple RNA–protein interactions may be subject to hormonally divergent regulation in a cell-specific manner. Clearly, we are only just beginning to unravel some of the complexities involved in the fine-tuning of basic cellular functions, such as the control of iron homeostasis. However, this work illustrates the central role that hormones have in the pituitary as regulators of RNA-binding protein binding-activity and intracellular iron concentrations.

CONCLUDING REMARKS

The main thrust of molecular research in understanding hormone action in the pituitary has, in the past, concentrated on transcriptional regulation and nuclear hormone receptor action. However, it is now evident that mRNA stability and hormonal regulation of RNA–protein interactions within pituitary cells also play a crucial role in regulating pituitary cellular function. Investigations in this field are adding to the global knowledge of RNA-binding proteins, RNA-stability sequences, the role of translation in mRNA stability, mechanisms of RNA degradation, and understanding of the molecular effects of hormone action in the pituitary. The cloning and characterization of novel pituitary RNA-binding proteins will allow, for the first time, a detailed analysis of the impact of these interactions on the vast secretory function of the pituitary gland.

REFERENCES

Adler GK, Rosen LB, Fiandaca MJ & Majzoub JA 1992 Protein kinase-C activation increases the quantity and poly(A) tail length of corticotropin-releasing hormone messenger RNA in NPLC cells. Molecular Endocrinology 6 476–484.

Afonina E, Neumann M & Pavlakis G 1997 Preferential binding of Poly(A) binding protein 1 to an inhibitory RNA element in the human immunodeficiency virus type 1 gag mRNA. Journal of Biological Chemistry 272 2307–2311.


Bernstein P, Pelitz S & Ross J 1989 The poly(A)-poly(A)-

Binding protein complex is a major determinant of mRNA


Coller JM, Gray NK & Wickens MP 1998 mRNA stabilization by poly(A) binding proteins is independent of poly(A) and requires translation. *Genes and Development* **12**, 3226–3234.


mRNA decay in the pituitary • J M Staton and others

Gallic D 1991 The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. Genes and Development 5 2108–2116.
Imataka H, Gradi A & Sonenberg N 1998 A newly identified N-terminal amino acid sequence of human eIF4 G binds
www.endocrinology.org

Fujimoto JM, Narayanan CS, Benjamin JE & Gershengorn MC 1992a Posttranscriptional up-regulation of thyrotropin-releasing hormone (TRH) receptor messenger ribonucleic acid by TRH in COS-1 cells transfected with mouse pituitary TRH receptor complementary deoxyribonucleic acid. Endocrinology 131 1716–1720.
Gallic D 1991 The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. Genes and Development 5 2108–2116.
Imataka H, Gradi A & Sonenberg N 1998 A newly identified N-terminal amino acid sequence of human eIF4 G binds...


Liebold EA & Munro H 1988 Cytoplasmic proteins bind in vitro to a highly conserved sequence in the 5′ untranslated region of ferritin heavy- and light-subunit mRNAs. PNAS 85 2171–2175.


Maurer F,Tierney M & Medcalf RL 1999 An AU-rich sequence in the 3′-UTR of plasminogen activator inhibitor type 2 (PAI-2) mRNA promotes PAI-2 mRNA decay and provides a binding site for nuclear HuR. Nucleic Acids Research 27 1664–1673.


Muckenthaler M, Gray NK & Hentze MW 1998 IRP binding to ferritin mRNA prevents the recruitment of small ribosomal subunit by the cap-binding complex. Molecular Cell 2 383–388.


Muhlrød D, Decker CJ & Parker R 1994 Deadenylation of the unstable mRNA encoded by the yeast MFA2 gene leads to decapping followed by 5′ to 3′ digestion of the transcript. Genes Development 8 855–866.


Paek I & Axel R 1987 Glucocorticoids enhance stability of growth hormone mRNA. Molecular and Cellular Biology 7 1496–1507.


www.endocrinology.org

Downloaded from Bioscientifica.com at 04/16/2019 04:49:24PM via free access


Shyu AB, Belasco JG & Greenberg ME 1991 Two distinct destabilizing elements in the c-fos message trigger deadenylation as the first step in rapid mRNA decay. Genes and Development 5 221–231.


Tanguay R & Gallie D 1996 Translational efficiency is regulated by the length of the 3′ untranslated region. Molecular and Cellular Biology 16 146–156.


Tuft M 1996 Death by decapitation for mRNA. Nature 382 577–579.


www.endocrinology.org


Zubiaga AM, Belasco JG & Greenberg ME 1995 The nonamer UUAUUUAUU is the key AU-rich sequence motif that mediates mRNA degradation. *Molecular and Cellular Biology* **15** 2219–2230.

**REVISED MANUSCRIPT RECEIVED 3 March 2000**